Washington Post releases a letter of potential consequences if legal brief filed in US Supreme Court

In a letter to the Editor published by the Washington Post, Keith Webber (former acting director of the FDA’s Office of Biotechnology Products and Office of Generic Drugs) highlighted the potential consequences of the legal brief filed in the US Supreme Court by the Trump administration. The Trump brief, filed on June 25, argues that the Affordable Care Act should be overturned as unconstitutional. Webber underscores that if Obamacare is overturned, the BPCIA would also be eliminated, removing the FDA’s ability to approve biosimilars and potentially effecting biosimilars previously approved.